BOLT
BOLT
NASDAQ · Biotechnology

Bolt Biotherapeutics Inc

$4.38
-0.12 (-2.67%)
Financial Highlights (FY 2026)
Revenue
7.48M
Net Income
-32,424,442
Gross Margin
Profit Margin
-433.7%
Rev Growth
+10.3%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 57.8% 57.8%
Operating Margin -469.3% -422.4% 7.8% 8.9%
Profit Margin -433.7% -412.1% 6.7% 7.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 7.48M 6.78M 3.98M 4.32M
Gross Profit 2.30M 2.50M
Operating Income -35,082,615 -28,618,103 310.2K 383.6K
Net Income -32,424,442 -26,449,739 267.7K 303.4K
Gross Margin 57.8% 57.8%
Operating Margin -469.3% -422.4% 7.8% 8.9%
Profit Margin -433.7% -412.1% 6.7% 7.0%
Rev Growth +10.3% +10.3% +11.2% +18.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 2.96M 2.24M
Total Equity 7.70M 8.12M
D/E Ratio 0.39 0.28
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -33,595,064 -28,927,137 477.9K 559.3K
Free Cash Flow 225.1K 222.9K